CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 64 enrolled
Drug / intervention
Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye dropsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00870103
NCT00870103Phase 4Completed
CompareCT.gov

An Evaluation of the Prophylactic Efficacy and Safety of the Administration of the Combination Formulation of Moxifloxacin 0.5% and Dexamethasone 0.1% Eye Drops in Inflammation and Infection Post-cataract Surgery

Alcon Research·interventional·Posted Mar 26, 2009·Updated Mar 9, 2010

In Brief

A Phase 4 clinical trial evaluating Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops for Cataract. Completed, enrolled 64 participants across 1 site.

Detailed Summary

To demonstrate that the combination formulation of Moxifloxacin/Dexamethasone Eye Drop is effective and safe for the prevention of postoperative inflammation as a consequence of cataract extraction surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 26, 2009
Enrollment StartSep 1, 2008
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 17.3 years ago

Interventions

Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye dropsdrug

1 drop every 6 hours into the study eye